Current Status of Bone-Forming Therapies for the Management of Osteoporosis

Sølling, Anne Sophie; Harsløf, Torben; Langdahl, Bente

doi:10.1007/s40266-019-00675-8

Cited by 21 publications

(19 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may include changing from oral to IV bisphosphonate, or switching therapy altogether to denosumab, teriparatide, or abaloparatide depending on the patient's age and co-morbidities. Two recent clinical trials comparing anabolic treatment with antiresorptive therapy have demonstrated that anabolic treatment may be superior in reducing fracture risk in women with severe postmenopausal osteoporosis [91].…”

Section: Monitoring and Duration Of Treatmentmentioning

confidence: 99%

Cystic fibrosis bone disease treatment: Current knowledge and future directions

Putman

Anabtawi

et al. 2019

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Bone disease is a frequent complication in adolescents and adults with cystic fibrosis (CF). Early detection and monitoring of bone mineral density and multidisciplinary preventive care are necessary from childhood through adolescence to minimize CF-related bone disease (CFBD) in adult CF patients. Approaches to optimizing bone health include ensuring adequate nutrition, particularly intake of calcium and vitamins D and K, addressing other secondary causes of low bone density such as hypogonadism, encouraging weight bearing exercise, and avoiding bone toxic medications. Of the currently available anti-resorptive or anabolic osteoporosis medications, only bisphosphonates have been studied in individuals with CF. Future studies are needed to better understand the optimal approach for managing CFBD.

show abstract

Section: Monitoring and Duration Of Treatmentmentioning

confidence: 99%

Cystic fibrosis bone disease treatment: Current knowledge and future directions

Putman

Anabtawi

et al. 2019

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…Moreover, teriparatide did not decrease the rates of mortality or deformity after fracture healing and did not decrease subsequent fracture or increase hip function. The above evidence seems that teriparatide plays a role in enhancing bone healing [ 32 ], without affecting other sides too much.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Teriparatide in Improving Fracture Healing in Hip Fractures: A Systematic Review and Meta-Analysis

Han

Wen

Zhao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. This systematic review and meta-analysis assessed the role of teriparatide in improving hip fracture healing and function to provide a clinical guide. Methods. The systematic literature review identified randomized controlled trials (RCTs) and controlled studies evaluating teriparatide for elderly hip fractures. A meta-analysis was performed using RevMan version 5.3. Results. This study included two RCTs and four retrospective studies comprising 607 patients, with 269 and 338 patients in the teriparatide and control groups, respectively. The quality of these six studies was moderate. Compared to the control group, teriparatide reduced the time to union (weighted mean difference WMD=−1.95; 95% confidence interval (CI): -3.23–-0.68; P=0.003) but did not improve the rate of fracture union at 3 months (odds ratio OR=1.46; 95% CI: 0.50–4.24; P=0.49) or 6 months (OR=0.89; 95% CI: 0.44–1.81; P=0.75). In addition, teriparatide did not decrease the complications, need for reoperation, mortality, rate of deformity after fracture healing, and subsequent fracture or improve hip function. Conclusions. The current limited evidence did not support that teriparatide improves fracture healing in hip fractures, due to study heterogeneity and various sources of biases. Further high-quality, large-sample trials are needed. This trial is registered with PROSPERO with registration number CRD42020152205.

show abstract

“…To date, three bone anabolic drugs are available in the clinic for the treatment of severe osteoporosis. Two of the drugs are based on the activation of the PTH receptor by an intermittent administration of a recombinant fragment of PTH (Teriparatide; Forteo/Forsteo) or Parathyroid hormone related protein (PTHrP; Abaloparatide) (49). Recently, the effect of PTH on breast cancer bone metastasis was investigated in two studies.…”

Section: Osteoblasts As Novel Target To Treat Bone Metastases-bone Anmentioning

confidence: 99%

“…The third bone anabolic agent is an antibody against the Wnt signaling inhibitor Sclerostin (Scl-Ab; Romosozumab) that increases bone formation and bone mass by activating the Wnt pathway in osteoblasts (49,53). In clinical trials, sclerostin antibody treatment of women with postmenopausal osteoporosis increased bone formation, while bone resorption was decreased, leading to an increase in bone mineral density and a reduction of the fracture rate at several sites, including the hip and spine (54).…”

Section: Osteoblasts As Novel Target To Treat Bone Metastases-bone Anmentioning

confidence: 99%

The Endosteal Niche in Breast Cancer Bone Metastasis

2020

View full text Add to dashboard Cite

The establishment of bone metastasis remains one of the most frequent complications of patients suffering from advanced breast cancer. Patients with bone metastases experience high morbidity and mortality caused by excessive, tumor-induced and osteoclast-mediated bone resorption. Anti-resorptive treatments, such as bisphosphonates, are available to ease skeletal related events including pain, increased fracture risk, and hypercalcemia. However, the disease remains incurable and 5-year survival rates for these patients are below 25%. Within the bone, disseminated breast cancer cells localize in "metastatic niches," special microenvironments that are thought to regulate cancer cell colonization and dormancy as well as tumor progression and subsequent development into overt metastases. Precise location and composition of this "metastatic niche" remain poorly defined. However, it is thought to include an "endosteal niche" that is composed of key bone cells that are derived from both, hematopoietic stem cells (osteoclasts), and mesenchymal stromal cells (osteoblasts, fibroblasts, adipocytes). Our knowledge of how osteoclasts drive the late stage of the disease is well-established. In contrast, much less is known about the interaction between osteogenic cells and disseminated tumor cells prior to the initiation of the osteolytic phase. Recent studies suggest that mesenchymal-derived cells, including osteoblasts and fibroblasts, play a key role during the early stages of breast cancer bone metastasis such as tumor cell homing, bone marrow colonization, and tumor cell dormancy. Hence, elucidating the interactions between breast cancer cells and mesenchymal-derived cells that drive metastasis progression could provide novel therapeutic approaches and targets to treat breast cancer bone metastasis. In this review we discuss evidences reporting the interaction between tumor cells and endosteal niche cells during the early stages of breast cancer bone metastasis, with a particular focus on mesenchymal-derived osteoblasts and fibroblasts.

show abstract

Current Status of Bone-Forming Therapies for the Management of Osteoporosis

Cited by 21 publications

References 68 publications

Cystic fibrosis bone disease treatment: Current knowledge and future directions

Cystic fibrosis bone disease treatment: Current knowledge and future directions

The Efficacy of Teriparatide in Improving Fracture Healing in Hip Fractures: A Systematic Review and Meta-Analysis

The Endosteal Niche in Breast Cancer Bone Metastasis

Contact Info

Product

Resources

About